Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs

Lung cancer expert Dr Rebecca Heist highlights the role of antibody-drug conjugates in the treatment of patients with advanced NSCLC, including their structure and mechanistic rationale, the latest clinical trial data, and key considerations for their application in the clinic.
Join the conversation and stay informed - touchoncologyime.org/emerging...
This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
#LungCancer
#Lung
#NSCLC
#ADCs
#CancerResearch